These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 21416059)

  • 1. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
    Kim HJ; Bae SC
    Am J Transl Res; 2011 Feb; 3(2):166-79. PubMed ID: 21416059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
    Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
    Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
    Ververis K; Hiong A; Karagiannis TC; Licciardi PV
    Biologics; 2013; 7():47-60. PubMed ID: 23459471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibitors in cancer care.
    Tofilon PJ; Camphausen K
    Oncology (Williston Park); 2010 Feb; 24(2):180-5. PubMed ID: 20361469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of histone deacetylase as antitumor agents: A critical review.
    Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
    Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
    Ma X; Ezzeldin HH; Diasio RB
    Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.
    Zhu WG; Otterson GA
    Curr Med Chem Anticancer Agents; 2003 May; 3(3):187-99. PubMed ID: 12769777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
    Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
    Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A
    Cells; 2018 Dec; 8(1):. PubMed ID: 30583560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
    Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
    Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
    Krishna S; Kumar V; Siddiqi MI
    Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting histone deacetylases in neuroblastoma.
    Witt O; Deubzer HE; Lodrini M; Milde T; Oehme I
    Curr Pharm Des; 2009; 15(4):436-47. PubMed ID: 19199971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.